Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

FDA Approves Neoadjuvant/Adjuvant Pembrolizumab for Resectable Non-Small Cell Lung Cancer

Evidence for efficacy is based on the results from KEYNOTE-671 study
30 Oct 2023
Immunotherapy;  Cytotoxic Therapy
Non-Small Cell Lung Cancer

On 16 October 2023, the US Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of single-agent pembrolizumab as post-surgical adjuvant treatment for resectable (tumours ≥4 cm or node positive) non-small cell lung cancer (NSCLC).

Full prescribing information for Keytruda is available here.

Efficacy was evaluated in KEYNOTE-671 (NCT03425643), a multicentre, randomised, double-blind, placebo-controlled study in 797 patients with previously untreated and resectable Stage II, IIIA, or IIIB (N2) NSCLC by AJCC 8th edition. Patients were randomised (1:1) to either pembrolizumab or placebo, with platinum-based chemotherapy, every 3 weeks for 4 cycles (neoadjuvant treatment) followed by either continued single-agent pembrolizumab or placebo, every 3 weeks for up to 13 cycles (adjuvant treatment). Chemotherapy details and surgical window are provided in the above drug label link.

The major efficacy outcome measures were overall survival (OS) and investigator-assessed event-free survival (EFS). Median OS was not reached in the pembrolizumab arm (95% confidence interval [CI] not estimable [NE], NE) and 52.4 months for those receiving placebo (95% CI 45.7, NE) (hazard ratio [HR] 0.72 [95% CI 0.56, 0.93]; p = 0.0103). Median EFS was not reached in the pembrolizumab arm (95% CI 34.1 months, NE) and 17 months in the placebo arm (95% CI 14.3, 22.0) (HR 0.58 [95% CI 0.46, 0.72]; p < 0.0001).

In KEYNOTE-671, the most common adverse reactions reported in ≥ 20% of patients were nausea, fatigue, neutropenia, anaemia, constipation, decreased appetite, white blood cell count decreased, musculoskeletal pain, rash, cough, vomiting, diarrhoea and dyspnoea. Of the patients who received neoadjuvant treatment in the pembrolizumab arm, 6% were unable to receive surgery due to adverse reactions compared with 4.3% in the placebo arm. In addition, 3.1% of patients who received neoadjuvant treatment and surgery in the pembrolizumab arm had delays in surgery due to adverse reactions compared with 2.5% in the placebo arm. Details of the safety of the neoadjuvant and adjuvant phases are described in the above drug label link.

The recommended pembrolizumab dose is 200 mg every 3 weeks or 400 mg every 6 weeks. Administer pembrolizumab prior to chemotherapy when administered on the same day.

This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.

For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact FDA’s Oncology Center of Excellence Project Facilitate.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.